Trial Profile

Phase-2 Study of Vedolizumab Plus Post-Transplant Cyclophosphamide and Short Course Tacrolimus for Graft-versus-Host Disease Prevention After Reduced Intensity Conditioning Peripheral Blood Stem Cell Allogeneic Hematopoietic Cell Transplantation

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 30 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cyclophosphamide (Primary) ; Tacrolimus (Primary) ; Tacrolimus (Primary) ; Vedolizumab (Primary) ; Melphalan
Indications Acute myeloid leukaemia; Graft-versus-host disease; Myelodysplastic syndromes; Myeloid leukaemia; Myeloproliferative disorders; Tuberculosis
Focus Adverse reactions; Therapeutic Use

24 Jun 2025 Planned End Date changed from 8 Jan 2028 to 15 Oct 2028.
24 Jun 2025 Planned primary completion date changed from 8 Jan 2028 to 15 Oct 2028.
24 Jun 2025 Status changed from not yet recruiting to recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com